Chronic obstructive pulmonary disease historical perspective
|
Chronic obstructive pulmonary disease Microchapters |
|
Differentiating Chronic obstructive pulmonary disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic obstructive pulmonary disease historical perspective On the Web |
|
American Roentgen Ray Society Images of Chronic obstructive pulmonary disease historical perspective |
|
FDA on Chronic obstructive pulmonary disease historical perspective |
|
CDC on Chronic obstructive pulmonary disease historical perspective |
|
Chronic obstructive pulmonary disease historical perspective in the news |
|
Blogs on Chronic obstructive pulmonary disease historical perspective |
|
Directions to Hospitals Treating Chronic obstructive pulmonary disease |
|
Risk calculators and risk factors for Chronic obstructive pulmonary disease historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Mehrian Jafarizade, M.D [2], Seyedmahdi Pahlavani, M.D. [3], Cafer Zorkun, M.D., Ph.D. [4]
Overview
For the first time, in 1679, Bonet described a condition of “voluminous lungs”. Matthew Baillie illustrated an emphysematous lung in 1789 and described the destructive character of the condition. In 1808, bronchitis was first described by Charles Badham in England. The terms chronic bronchitis and emphysema were formally defined at the CIBA guest symposium of physicians in 1959. COPD has probably always existed but has been called by different names in the past. The term COPD was first used by William Briscoe in 1965 and has gradually overtaken other terms to become established today as the preferred name for this disease.
Historical Perspective
- In 1679, Bonet for the first time described voluminous lungs.
- In 1721, Ruysh described enlarged lung airspaces in emphysema.
- In 1769, Giovanni Morgagni described nineteen cases in which the lungs were “turgid” particularly from air.
- In 1789, Matthew Baillie illustrated an emphysematous lung and described the destructive character of the condition.
- In 1808, bronchitis was first described by Charles Badham in England. He classified acute bronchitis to three forms by his definition (Br. acuta, asthenica and chronica)[1]
- In 1837, René Laennec, the physician who invented the stethoscope, used the term "emphysema" in his book A Treatise on the Diseases of the Chest and of Mediate Auscultation to describe lungs that did not collapse when he opened the chest during an autopsy. He noted that they did not collapse as usual because they were full of air and the airways were filled with mucus.[2]
- In 1842, John Hutchinson invented the spirometer, which allowed the measurement of the vital capacity of the lungs. However, his spirometer could only measure volume, not airflow.[3]
- In 1944, Ronald Christie defined the diagnosis for emphysema based on dyspnea on exertion, after exclusion of bronchospasm, or left ventricular failure.
- In 1947, Tiffeneau and Pinelli, and in 1950 and 1951, Gaensler described the principles of measuring airflow.
- in 1952, Gough explained the pathology of emphysema.
- In 1956, Barach and Bickerman described treatment for emphysema in their comprehensive textbook.
- In 1959, the terms chronic bronchitis and emphysema were formally defined at the CIBA guest symposium of physicians.
- In 1962, American Thoracic Society Committee on Diagnostic Standards defined the components of COPD and this definition is the foundation of COPD description today.
- In 1964, Gross produced destruction of alveoli and hyperinflation, by injection of pancreatic extracts (papain) into the airways of guinea pigs.
- In 1965, the term COPD was first used by William Briscoe and has gradually overtaken other terms to become established today as the preferred name for this disease.
- In 1967, Reid described the pathology of emphysema and other components of COPD.
- In 1976, Thurlbeck illustrated the various types of emphysema in his book.
- In 2003, Choe used methylprednisolone to produce emphysema in rats. They conclude that systemic methylprednisolone increases the activity of matrix metalloproteinases in the lung and causes emphysema. [4]
- In 2004, GOLD offered a new classification of the severity of COPD. [5]
- In 2005, Voelkel and Taraseviciene-Stewart offered emphysema as an autoimmune vascular disease. [6]
Landmark Events in the Development of Treatment Strategies
- In 1956, Barach and Bickerman described treatment for emphysema in their comprehensive textbook.
- In 1980, for treatment of COPD patients, a clinical trial was performed and the use of nocturnal oxygen therapy for emphysema proved. [7]
- In 1998, Paggiaro performed a multicentre clinical trial of corticosteroids for emphysema treatment.[8]
Below table is a summery of COPD historical prospective:
| Year | Investigator | Landmark event |
|---|---|---|
| 1679 | Bonet | Voluminous lungs |
| 1721 | Ruysh | Emphysema is enlarged lung spaces |
| 1769 | Giovanni Morgagni | Nineteen cases of air filled lungs |
| 1789 | Matthew Baillie | Destructive character of emphysema |
| 1808 | Charles | Bronchitis was first described |
| 1837 | René Laennec | Hyper-resonant lungs with his invented stethoscope |
| 1842 | John Hutchinson | Spirometry invention for measurement of the vital capacity of the lungs |
| 1944 | Ronald Christie | Clinical definition of emphysema |
| 1947 | Tiffeneau and Pinelli | Measuring the air flow in spirometry |
| 1952 | Gough | Emphysema pathology description |
| 1956 | Barach and Bickerman | First description for treatment of emphysema |
| 1959 | CIBA guest symposium of physicians | The terms chronic bronchitis and emphysema were formally defined |
| 1962 | American Thoracic Society Committee on Diagnostic Standards | Defined the components of COPD |
| 1967 | Reid | Described the pathology of emphysema and other components of COPD |
| 1976 | Thurlbeck | Illustrated the various types of emphysema |
| 1980 | Oxygen therapy trial | Use of nocturnal oxygen therapy for emphysema is beneficial |
| 1998 | Paggiaro | Corticosteroids for emphysema treatment |
| 2004 | GOLD criteria | New classification of the severity of COPD |
| 2005 | Voelkel and Taraseviciene-Stewart | Emphysema as an autoimmune vascular disease |
References
- ↑ Klippe HJ, Kirsten D (2009). "[200 years of bronchitis--from 1808 to 2008]". Pneumologie (in German). 63 (4): 228–30. doi:10.1055/s-0028-1119572. PMID 19343614.
- ↑ Petty TL (2006). "The history of COPD". Int J Chron Obstruct Pulmon Dis. 1 (1): 3–14. PMC 2706597. PMID 18046898.
- ↑ Fishman AP (2005). "One hundred years of chronic obstructive pulmonary disease". Am. J. Respir. Crit. Care Med. 171 (9): 941–8. doi:10.1164/rccm.200412-1685OE. PMID 15849329. Unknown parameter
|month=ignored (help) - ↑ Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF (2003). "Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats". Am. J. Respir. Crit. Care Med. 167 (11): 1516–21. doi:10.1164/rccm.200210-1207OC. PMID 12522028.
- ↑ "Global Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD".
- ↑ Voelkel N, Taraseviciene-Stewart L (2005). "Emphysema: an autoimmune vascular disease?". Proc Am Thorac Soc. 2 (1): 23–5. doi:10.1513/pats.200405-033MS. PMID 16113465.
- ↑ "Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group". Ann. Intern. Med. 93 (3): 391–8. 1980. PMID 6776858.
- ↑ Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J (1998). "Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group". Lancet. 351 (9105): 773–80. PMID 9519948.